{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:45:28Z","timestamp":1787161528499,"version":"build-2736575974"},"reference-count":15,"publisher":"Japan Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1507\/endocrj.ej18-0243","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T18:23:15Z","timestamp":1534789395000},"page":"1121-1125","source":"Crossref","is-referenced-by-count":12,"title":["The effect of anti-TNF therapy on thyroid function in patients          with inflammatory bowel disease"],"prefix":"10.1507","volume":"65","author":[{"given":"Stavroula A.","family":"Paschou","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, Greece"},{"name":"Division of Endocrinology and Diabetes, \u201cAghia Sophia\u201d Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Palioura","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Kothonas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hellenic Red Cross Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Myroforidis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hellenic Red Cross Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Loi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Androniki","family":"Poulou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hellenic Red Cross Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Goumas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hellenic Red Cross Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigoris","family":"Effraimidis","sequence":"additional","affiliation":[{"name":"Department of Medical Endocrinology, Rigshospitalet University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andromachi","family":"Vryonidou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","unstructured":"1 Snook JA, de Silva HJ, Jewell DP (1989) The association of autoimmune disorders with inflammatory bowel disease. Q J Med 72: 835\u2013840."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Inokuchi T, Moriwaki Y, Takahashi S, Tsutsumi Z, Ka T, et al. (2005) Autoimmune thyroid disease (Graves\u2019 disease and hashimoto\u2019s thyroiditis) in two patients with Crohn\u2019s disease: case reports and literature review. Intern Med 44: 303\u2013306.","DOI":"10.2169\/internalmedicine.44.303"},{"key":"3","doi-asserted-by":"crossref","unstructured":"4 Cohen BL, Sachar DB (2017) Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ 357: j2505.","DOI":"10.1136\/bmj.j2505"},{"key":"4","doi-asserted-by":"crossref","unstructured":"5 Raterman HG, Jamnitski A, Lems WF, Voskuyl AE, Dijkmans BA, et al. (2011) Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study. J Rheumatol 38: 247\u2013251.","DOI":"10.3899\/jrheum.100488"},{"key":"5","doi-asserted-by":"crossref","unstructured":"7 Chen K, Wei Y, Sharp GC, Braley-Mullen H (2007) Decreasing TNF-alpha results in less fibrosis and earlier resolution of granulomatous experimental autoimmune thyroiditis. J Leukoc Biol 81: 306\u2013314.","DOI":"10.1189\/jlb.0606402"},{"key":"6","unstructured":"8 Tigas S, Tsatsoulis A (2012) Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol 25: 37\u201344."},{"key":"7","doi-asserted-by":"crossref","unstructured":"9 Shizuma T (2016) Concomitant thyroid disorders and inflammatory bowel disease: a literature review. Biomed Res Int 2016: 5187061.","DOI":"10.1155\/2016\/5187061"},{"key":"8","doi-asserted-by":"crossref","unstructured":"10 Casella G, De Marco E, Antonelli E, Daperno M, et al. (2008) The prevalence of hyper- and hypothyroidism in patients with ulcerative colitis. J Crohns Colitis 2: 327\u2013330.","DOI":"10.1016\/j.crohns.2008.09.001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"11 Pooran N, Singh P, Bank S (2003) Crohn\u2019s disease and risk of fracture: does thyroid disease play a role? World J Gastroenterol 9: 615\u2013618.","DOI":"10.3748\/wjg.v9.i3.615"},{"key":"10","doi-asserted-by":"crossref","unstructured":"12 D\u00edez JJ, Hernanz A, Medina S, Bay\u00f3n C, Iglesias P (2002) Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol (Oxf) 57: 515\u2013521.","DOI":"10.1046\/j.1365-2265.2002.01629.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"13 Miyakoshi H, Ohsawa K, Yokoyama H, Nagai Y, Ieki Y, et al. (1992) Exacerbation of hypothyroidism following tumor necrosis factor-alpha infusion. Intern Med 31: 200\u2013203.","DOI":"10.2169\/internalmedicine.31.200"},{"key":"12","doi-asserted-by":"crossref","unstructured":"14 van der Poll T, Romijn JA, Wiersinga WM, Sauerwein HP (1990) Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab 71: 1567\u20131572.","DOI":"10.1210\/jcem-71-6-1567"},{"key":"13","doi-asserted-by":"crossref","unstructured":"15 Maia AL, Goemann IM, Meyer EL, Wajner SM (2011) Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease. J Endocrinol 209: 283\u2013297.","DOI":"10.1530\/JOE-10-0481"},{"key":"14","doi-asserted-by":"crossref","unstructured":"16 Shupnik MA (2000) Thyroid hormone suppression of pituitary hormone gene expression. Rev Endocr Metab Disord 1: 35\u201342.","DOI":"10.1023\/A:1010008318961"},{"key":"15","doi-asserted-by":"crossref","unstructured":"17 Ogiwara T, Araki O, Morimura T, Tsunekawa K, Mori M, et al. (2013) A novel mechanism for the inhibition of type 2 iodothyronine deiodinase by tumor necrosis factor \u03b1: involvement of proteasomal degradation. Endocr J 60: 1035\u20131045.","DOI":"10.1507\/endocrj.EJ11-0144"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/65\/11\/65_EJ18-0243\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T23:03:20Z","timestamp":1543619000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/65\/11\/65_EJ18-0243\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej18-0243","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}